Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image

Résumé fourni par la source

Motivation: Non-invasive prediction of GBM’s pMGMT methylation status is still challenging despite recent advancements of image analysis. Goal(s): This study explored a clinically feasible imaging biomarker that represents GBM’s pMGMT methylation status with external validation. Approach: Two qualitative imaging features, namely the “Thickened structure” and the “Methylated contrast phenotype,” were identified as valuable to this means. Results: GBMs presenting both imaging features exhibited a significantly high odds ratio, favoring pMGMT methylation in the exploratory and validation cohorts with a sensitivity and specificity of approximately 0.3-0.4 and 0.8. The easy clinical application of the proposed imaging features is expected to facilitate better preoperative GBM characterization. Impact: GBMs presenting both imaging features, namely the “Thickened structure” and the “Methylated contrast phenotype,” exhibited a significantly high odds ratio, favoring pMGMT methylation in the exploratory and validation cohorts with a sensitivity and specificity of approximately 0.3-0.4 and 0.8.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.